Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy, has previously demonstrated promising results in treating chronic graftversus-host disease (cGvHD). We treated six patients (ages 33-54 years) with long-standing refractory extensive-stage cGvHD. ECP was performed thrice weekly initially in all patients. Concomitant therapies included prednisone (n ¼ 6), tacrolimus (n ¼ 5), cyclosporin A (n ¼ 2), hydroxychloroquine (n ¼ 2), mycophenolate mofetil (n ¼ 1), and psoralen plus ultraviolet A radiation (n ¼ 1). After an average of 7.2 months (range, 2-13 months) of ECP, all patients experienced either improvement or stabilization in sclerodermatous skin changes, as well as partial improvements in liver enzyme levels. Skin softening occurred in four patients and was noted as early as 3-8 weeks into treatment. Two patients were able to taper steroid therapy, and two patients were able to taper ECP to twice weekly. ECP was well tolerated. Our results support those of previous studies, suggesting that ECP may be beneficial in patients with refractory cGvHD.
chronic graft-versus-host disease; extracorporeal photochemotherapy; photopheresis Chronic graft-versus-host disease (cGvHD) is the most common complication of allogeneic bone marrow transplantation (BMT), affecting approximately 50% of longterm survivors. 1 Histologically, cGvHD is characterized by increased collagen deposition in target organs. 2 Clinically, it is analogous to autoimmune disorders, particularly progressive systemic sclerosis. The pathogenesis of cGvHD is not clear, but may involve activation of donor-derived alloreactive and/or host-derived autoreactive T-helper lymphocytes. 3 First-line therapy, which consists of corticosteroids alone or in combination with cyclosporin A, achieves complete responses in approximately 50% of patients. 4 Even with aggressive treatment, cGvHD is associated with a significant degree of morbidity and mortality, with deaths occurring in 20-40% of patients. 5 Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy approved for the palliative treatment of advanced cutaneous T-cell lymphoma (CTCL), 6 and used investigationally in several autoimmune diseases and organ transplant rejection, 7 has demonstrated promising results in treating cGvHD in small, uncontrolled studies. [8] [9] [10] [11] [12] ECP entails the collection of a small amount (2-5%) of peripheral blood mononuclear cells by apheresis, exposure of this cell fraction to ultraviolet A (UVA) radiation in the presence of the photosensitizing agent 8-methoxypsoralen (8-MOP) in an extracorporeal flow system, and subsequent reinfusion of the exposed cells. 6 This modality's mechanism of action may involve modifications in T-cell activity and cytokine profiles.
6,7 Herein, we describe our experience with ECP in treating six patients with long-standing refractory extensive-stage cGvHD.
Methods
Eligible patients were X18 years of age and had a diagnosis of extensive-stage cGvHD following allogeneic BMT. Extensive-stage cGvHD is defined as either: (1) generalized skin involvement or (2) localized skin involvement and/or hepatic dysfunction because of cGvHD, plus one of the following: liver histology showing chronic aggressive hepatitis, bridging necrosis, or cirrhosis; involvement of the eye (Schimer's test with less than 5 mm wetting); involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy; or involvement of any other target organ. 2 Patients were treated between August 2000 and December 2001 at an outpatient facility that specializes in ECP at Morristown Memorial Hospital, Morristown, NJ, USA. Patients were eligible for ECP regardless of the use or type of previous therapies.
ECP was performed using the UVAR s XTSt system (THERAKOS, Inc). With this system, a small portion of the patient's blood is obtained through an antecubital indwelling venous catheter, with the machine calculating the amount of blood to be removed based on the patient's hematocrit. The blood is then separated into erythrocytes and buffy coat via centrifugation. Erythrocytes are returned to the patient, while the buffy coat fraction is treated with soluble 8-MOP (UVADEX s ; THERAKOS, Inc), at a concentration of 20 mg/ml, and subsequently irradiated with UVA light, at wavelengths ranging from 320 to 400 nm. The volume of 8-MOP solution added is based on the following formula: UVADEX volume ¼ collected treatment volume Â 0.017. A treatment of ECP lasts 3-4 h. At the conclusion of the treatment, the irradiated buffy coat fraction is reinfused. The initial ECP frequency in this study was three times per week (alternating days), with the frequency decreased to twice or once per week, depending upon patient response. Concomitant therapies for cGvHD were used as necessary and included cyclosporin A, hydroxychloroquine, mycophenolate mofetil, prednisone, psoralen plus ultraviolet A radiation (PUVA), and tacrolimus. In addition, all patients received standard antimicrobial prophylaxis.
Patients referred for ECP received baseline evaluations, which included a complete history and physical examination, laboratory tests, and skin assessment. Skin was evaluated by the modified scleroderma skin scoring method whereby 22 body areas are palpated and scored on the 
following scale: 0 ¼ normal; 1 ¼ thickened; 2 ¼ thickened, unable to move; and 3 ¼ thickened, unable to pinch (with a possible maximum score of 66). 13 Clinical status was reevaluated weekly.
Results
Six consecutive cGvHD patients presented with sclerodermatous skin changes and systemic disease ( Table 1 ). All patients had failed first-and second-line therapy. Patients 1 and 3 had a history of acute GvHD. The mean time between BMT and ECP was 29.5 months (range, 18-43 months). Patients were treated with ECP for an average of 7.2 months (range, 2-13 months) ( Table 2 ). All patients experienced either improvement or stabilization in skin manifestations and overall disease activity (Table 3) . Skin softening occurred in four patients (1, 4, 5, and 6) and was noted as early as 3-8 weeks after ECP initiation. Patient 5, who at baseline displayed hyperpigmentation and sclerodermatous changes involving 30-40% of her body, demonstrated a 67% decline in scleroderma skin score after 10 months of ECP. Patient 4, who at baseline had a hyperpigmented reticular-patterned maculopapular rash and severe sclerodermatous changes over his entire body, also displayed marked cutaneous improvement after 10 months of ECP, with improvements in physical function. Partial improvements in liver enzyme levels were noted in five patients (1) (2) (3) (4) (5) . Thrombocytopenia normalized in patient 1 after 13 months of ECP. Mouth ulcers disappeared in patient 1 and stabilized in patient 2.
Two patients (2 and 5) were able to taper prednisone therapy, and two patients (1 and 5) were able to taper ECP to twice weekly ( Table 2) . Patient 1 was in the process of reducing prednisone and tacrolimus at the end of the study period. An increase in dose and/or initiation of new immunosuppressive therapy during the study period occurred in two patients (1 and 2), precluding adequate evaluation of the effects of ECP in these patients.
ECP was generally well tolerated. In patient 5, hemoglobin and hematocrit dropped at week 6 of ECP, necessitating transfusion and erythropoietin therapy. In patient 6, hemoglobin dropped at week 4 of ECP, necessitating erythropoietin therapy. No patients developed infections at the venous catheter site.
Discussion
Our experience confirms that ECP is feasible even after several months of refractory cGvHD. All six patients in this series demonstrated stabilization in overall disease activity, and three patients (4, 5, and 6) experienced prompt skin softening when ECP was used with steady or decreasing doses of concomitant therapies. Sclerodermatous cGvHD represents a formidable therapeutic challenge because sclerosis resolves slowly, if at all. Patients with active a Modified scleroderma skin score was determined by palpation of 22 body areas and scoring on the following scale: 0=normal; 1=thickened; 2=thickened, unable to move; and 3=thickened, unable to pinch (with a possible maximum score of 66). disease display progressive sclerosis and, frequently, erythema at the leading edge of sclerosis, whereas responding patients have neither new areas of sclerosis nor erythema. 14 By this definition, all of our patients were clinical responders. Such results are relevant because cGvHD patients with extensive disease, liver dysfunction, or concomitant thrombocytopenia have a poor prognosis. 5 Our results expand upon those of previous reports in small groups of cGvHD patients treated with ECP. [8] [9] [10] [11] [12] The precise mechanism by which ECP evokes responses in cGvHD, as well as other T-cell-mediated disorders, is not known, but may involve modifications in T-cell activity and cytokine profiles. 6, 7 Emerging evidence indicates that ECP works through several mechanisms of action and that these mechanisms may be dependent on the underlying disease state. Upon exposure to UVA radiation, 8-MOP covalently binds to nucleic acids, proteins, and lipids, potentially triggering yet undefined cellular signaling events. Experimental and clinical data suggest that the reinfusion of peripheral mononuclear cells previously exposed to 8-MOP and UVA radiation may engender a vaccination-like response against rapidly expanding pathogenic T-cell clones, without general immunosuppression. 6, 7 For instance, in (C57BL/6 Â DBA/2)F1 (B6D2F1) mice that, when inoculated with parental DBA/2 (D2) splenocytes, develop chronic stimulatory graft-versus-host reaction with clinical manifestations of systemic lupus erythematosus (SLE), inoculation of 8-MOP-UVA-radiation-exposed D2 splenocytes inhibited the progression of GvHD-initiated SLE-like disease that had been previously elicited by inoculation of unexposed D2 splenocytes. 15 Moreover, in a recent study with 10 cGvHD patients treated with ECP for two consecutive days every 2 weeks for 6-12 months, seven patients who achieved a clinical response (improvement in skin changes) had initially displayed clonal populations of alloreactive T cells by spectra type analysis, whereas nonresponding patients had not. 12 New research with cGVHD suggest that ECP leads to attenuation of Th1-mediated cytokine secretion, a shift in the DC1/DC2 ratio towards plasmacytoid rather than monocytoid dendritic cell profiles, and diminished dendritic-cell antigen responsiveness. 16 Such findings are important because Th1 cytokines such as interferon-g are believed to play a central role in the increased collagen deposition in cGvHD patients. 17 Furthermore, in an earlier study, lymphocytes isolated from GvHD patients following ECP demonstrated significantly increased levels of apoptosis, 17 suggesting a possible direct mechanism for the deletion of effector T cells. Thus, in the setting of continuing autoreactivity and alloreactivity in cGvHD, ECP may inhibit activated T lymphocytes as well as antigen-presenting cells, attenuating Th1-mediated processes. 16 The clinical significance of these findings needs to be established.
Currently, there is no standard therapeutic approach to treating patients with refractory cGvHD who develop function-limiting sclerodermatous skin changes. The clinical observations we describe here further suggest that ECP may have a role in salvage therapy of cGvHD. At this time, it is unclear whether ECP can prevent end-organ damage, modify the natural course of the disease, or increase survival among patients with cGvHD. Consequently, controlled long-term prospective studies are needed to further evaluate the clinical utility of ECP in the treatment of cGvHD.
